Vanguard Investments Australia
HAE icon

Vanguard Investments Australia’s Haemonetics HAE Stock Holding History

Vanguard Investments Australia’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$881K Hold
11,741
– – ﹤0.01% 1357
2026
Q1 		$662K Buy
+11,741
New +$765K ﹤0.01% 1442

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Investments Australia's HAE Position: Q2 2026 in Review

Vanguard Investments Australia held its Haemonetics (HAE) position steady in Q2 2026 at 11,741 shares worth $881K. The position accounts for ﹤0.01% of the portfolio, ranked #1357.

Vanguard Investments Australia first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Vanguard Investments Australia held 11,741 shares of Haemonetics worth $881K as of Q2 2026.
  • Vanguard Investments Australia left its Haemonetics share count unchanged in Q2 2026.
  • Haemonetics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1357 holding.
  • Vanguard Investments Australia first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.